Dosage individualization of erythropoietin using a profile-dependent support vector regression

被引:31
作者
Martín-Guerrero, JD
Camps-Valls, G
Soria-Olivas, E
Serrano-López, AJ
Pérez-Ruixo, JJ
Jiménez-Torres, NV
机构
[1] Univ Valencia, Fac Fis, Dpt Eng Elec, Digital Signal Proc Grp, E-46100 Burjassot, Spain
[2] Dr Peset Univ Hosp, Serv Pharm, Valencia 46017, Spain
[3] Univ Valencia, Pharm & Pharmaceut Technol Dept, E-46100 Burjassot, Spain
关键词
anemia; chronic renal failure; clinical pharmacokinetics; drug monitoring; erythropoietin; neural networks; support vector method; time series prediction;
D O I
10.1109/TBME.2003.816084
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
The external administration of recombinant human erythropoietin is the chosen treatment for those patients with secondary anemia due to chronic renal failure in periodic hemodialysis. The objective of this paper is to carry out an individualized prediction of the EPO dosage to be administered to those patients. The high cost of this medication, its side effects and the phenomenon of potential resistance which some individuals suffer all justify the need for a model which is capable of optimizing dosage individualization. A group of 110 patients and several patient factors were used to develop the models. The support vector regressor (SVR) is benchmarked with the classical multilayer perceptron (MLP) and the Autoregressive Conditional Heteroskedasticity (ARCH) model. We introduce a priori knowledge by relaxing or tightening the epsilon-insensitive region and the penalization parameter depending on the time period of the patients' follow-up. The so-called profile-dependent SVR (PD-SVR) inproves results of the standard SVR method and the MLP. We perform sensitivity analysis on the MLP and inspect the distribution of the support vectors in the input and feature spaces in order to gain knowledge about the problem.
引用
收藏
页码:1136 / 1142
页数:7
相关论文
共 23 条
[1]  
[Anonymous], LNCS, DOI DOI 10.1007/BFB0020283
[2]   DRUG DELIVERY OPTIMIZATION THROUGH BAYESIAN NETWORKS - AN APPLICATION TO ERYTHROPOIETIN THERAPY IN UREMIC ANEMIA [J].
BELLAZZI, R .
COMPUTERS AND BIOMEDICAL RESEARCH, 1993, 26 (03) :274-293
[3]  
BRADLEY PS, 1998, 9801 U WINSC COMP SC
[4]   European best practice guidelines for the management of anaemia in patients with chronic renal failure [J].
Cameron, JS .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 :61-65
[5]  
CAMPSVALLS G, 2002, I ELECT ENG ELECT LE, V38
[6]  
CAMPSVALLS G, 2001, NEUR INF PROC SYST N
[7]  
CAMPSVALLS G, LECT NOTES COMPUTER, V2130, P706
[8]  
CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1023/A:1022627411411
[9]   AUTOREGRESSIVE CONDITIONAL HETEROSCEDASTICITY WITH ESTIMATES OF THE VARIANCE OF UNITED-KINGDOM INFLATION [J].
ENGLE, RF .
ECONOMETRICA, 1982, 50 (04) :987-1007
[10]   ANEMIA OF END-STAGE RENAL-DISEASE (ESRD) [J].
ESCHBACH, JW ;
ADAMSON, JW .
KIDNEY INTERNATIONAL, 1985, 28 (01) :1-5